Corporate Introduction

GenScript Biotech Corporation (HK.1548) is an important technology and service provider in the world for life science R&D and manufacture. Built upon its solid DNA synthesis technology, GenScript Biotech comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and an integrated global cell therapy company.
Read More »

* As of December 31st, 2023

Corporate History

2023
2022
2021
2020
2019
2018
2017
2015
2014
2013
2011
2009
2004
2002
GenScript 2023
  • 2023, Bestzyme successfully secured financing of RMB 250 million
  • Legend Biotech and Novartis Pharma AG (Novartis) have entered an exclusive, worldwide license agreement for certain Legend Biotech CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3)
GenScript 2022
  • 2022 Legend Biotech‘s CARVYKTI™ (Cilta-cel) received U.S. FDA approval, conditional approval by the European regulatory body
  • Commission (EC) and approval by Japan’s Ministry of Health, Labor and Welfare (MHLW)
  • China's largest commercial GMP plasmid manufacturing facility officially established by ProBio in Zhenjiang, Jiangsu
  • Singapore manufacturing and R&D center officially opened
GenScript 2021- cPass™
  • Hillhouse Capital invested over US$ 1 billion in the Group and Legend Biotech
  • cPass™ SARS-CoV-2 neutralization antibody detection kit and its sVNT serological detection method both received the notices of allowance of US patent application
  • Provided plasmid products and services for the first batch of COVID-19 mRNA vaccine projects
  • Legend Biotech submitted NDA for Cilta-cel (CARVYKTI™) in Japan
  • China's largest commercial GMP plasmid manufacturing facility officially opened
GenScript 2020- Probio
  • Developed the world's first cPass™ SARS-CoV-2 neutralization antibody fast detection kit with Singapore to jointly fight COVID-19
  • Legend Biotech listed on NASDAQ, the largest IPO for a biotech segment year to date
  • Cilta-cel (CARVYKTI™) was granted China‘s first “breakthrough therapy designation” and submitted BLA to FDA US
  • Biologics CDMO business unit launched its brand name, ProBio
GenScript 2019- EMA
  • Launched new Biologics GMP CDMO R&D center
  • Established European & Asia-Pacific Division
  • Cilta-cel (CARVYKTI™) received Orphan Drug Designation (FDA) & PRIME Designation (EMA), US phase 1b data at ASH 2019: ORR 100%
GenScript 2018- FDA
  • Cilta-cel (CARVYKTI™) received IND clearance in US and China, progressing smoothly in both US & China
  • Biologics CDMO segment officially established
GenScript 2017- Janssen
  • Legend and Janssen entered into collaboration on Cilta-cel (BCMA program)
  • CFDA accepted the IND application by Legend Biotech
  • Acquired CustomArray Inc.
GenScript 2015- HKEX
  • GenScript Biotech listed in HKEX (HK.1548)
GenScript 2014- Legend Biotech
  • Launched Legend Biotech (the cell therapy segment)
  • Received CRO Leadership Award
GenScript 2013- Bestzyme
  • Launched the Bestzyme (biotech industrial synthetic biology) product segment
GenScript 2012- Science
  • New research and production facility opened in Nanjing
  • Selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0 Project
  • Established subsidiary in Japan
GenScript 2009- KPCB TBIG
  • KPCB / TBIG Healthcare investment
GenScript 2004- Nanjing, China
  • Introduced Custom Protein and Antibody Service
  • Established research and production center in Nanjing, China
GenScript 2002- New Jersey, US
  • GenScript Founded in New Jersey, USA

Our Vision

Become the Most Trustworthy Biotech Company in the World

Our Mission

Make People and Nature Healthier Through Biotechnology

Our Spirit

Dare To Win!

Key Facts

Proven Gene Expertise

As the leading gene synthesis provider in the world, our gene synthesis tools are designed to make research accessible. Our propriety, population immune algorithm based GenSmart codon optimization technology enables the design of the most expression-efficient sequence available, while our CloneArk™ system provides a platform for researchers to archive, share and reuse their clones for future use with peace of mind.

Reliable Synthetic Peptides

Powered by advanced PepPower™ synthesis technology platform and supported by stringent quality management systems, GenScript synthesizes more than 25,000 peptides/month, featured with variety of custom modifications, delivery options, and high level of batch-to-batch consistency

Proprietary MonoRab™ Antibody

Powered by a unique B-cell cloning protocol, GenScript allows our clients to test for antibodies that work in their application before sequencing the desired clones for recombinant antibody production. Work with us to generate exclusive, custom rabbit monoclonal antibodies that are high in sensitivity, affinity and specificity for your research and diagnostic needs.

Premier High-Throughput Gene to Antibody Production

Designed to accelerate the drug screening process, GenScript helps researchers identify promising candidate leads and advance to the production of purified recombinant antibodies with one of the fastest turnaround times in the industry.

Licensed CRISPR/Cas9 Genome Editing

Through partnership with the technology's pioneering Broad Institute of MIT and Harvard, as well as ERS Genomics, GenScript offers a variety of CRISPR services, including guide RNA design tools, pre-validated CRISPR plasmids, and learning resources to help scientists harness the power of CRISPR genome editing in life science research.

feedback

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*